Active implanted stimulation devices have been utilized for applications such as pacing, defibrillation, spinal and gastric stimulation. Such devices typically include wired electrodes on a lead module hardwired to an implanted pulse generator (IPG) that contains an internal battery that can be recharged periodically with an inductive coil recharging system.
In one aspect, a system includes a control module including a first antenna, the control module being configured to generate a first radio frequency (RF) signal and transmit the first RF signal using the first antenna; an implantable lead module including a second antenna and at least one electrode configured to stimulate excitable tissue of a subject; and a relay module configured to: receive the first RF signal; generate a second RF signal based on the first RF signal with the second RF signal encoding a stimulus waveform to be applied to the electrodes of the implantable lead module to stimulate excitable tissue of a subject; and transmit the second RF signal, wherein the implantable lead module is configured to receive the second RF signal using the second antenna, generate the stimulus waveform from the received second RF signal, and apply the stimulus waveform to the excitable tissue of the subject.
Implementations of this and other aspects may include the following features: a control module which may include a programming interface to allow a user to adjust parameters of the stimulation waveform; a first antenna of the control module which may include a dipole antenna, a folded dipole antenna, a microstrip antenna, or a phased array of antennas.
The relay module may include: a receive antenna layer configured to receive the first RF signal transmitted by the first antenna of the control module; at least one dielectric insulating layer; and a transmit antenna layer separated from the receive antenna layer by the dielectric insulating layer, the transmit antenna layer being configured to transmit the second RF signal to the second antenna of the implantable lead module, the second RF signal being generated based on the first RF signal, and the second RF signal encoding a stimulus waveform to be applied by the at least one electrode of the implantable lead module to stimulate the excitable tissue of the subject.
The receive antenna layer of the relay module may include one of: a patch antenna, or a dipole antenna. The receive antenna layer may further include at least one quarter wavelength antenna. The transmit antenna layer of the relay module may include one of: a patch antenna, or a dipole antenna. The transmit antenna layer may further include at least one quarter wavelength antenna.
The relay module may further include a flexible circuit, wherein the flexible circuit may include a rectifier and a capacitor, and wherein the capacitor is coupled to the rectifier and configured to store a charge during an initial portion of the first RF signal. The flexible circuit may further include a counter configured to cause the flexible circuit to generate a trigger upon an end of the initial portion. The flexible circuit may further include an oscillator, coupled to the counter and configured to generate, upon the trigger, a carrier signal, and wherein the flexible circuit may modulate the carrier signal with a stimulus waveform encoded in the first RF signal to generate the second RF signal. The flexible circuit may be configured to generate the second RF signal based on the stimulus waveform during a stimulation portion of the first RF signal, wherein the second RF signal has a corresponding carrier frequency that is substantially identical to that of the first RF signal. The flexible circuit may further include a power amplifier configured to amplify the second RF signal, and wherein the transmit antenna layer may be configured to transmit the amplified second RF signal to the second antenna of the implantable lead module. The power amplifier may be powered by the charge stored in the capacitor during the initial portion of the first RF signal. The oscillator may be triggered by an amplitude shift keying in the first RF signal.
The first RF signal and the second RF signal may have respective carrier frequencies that may be within a range of about 800 MHz to about 6 GHz. The respective carrier frequencies of the first and second RF signals may be different.
The relay module may be placed exterior to the subject and the relay module may further include a battery. The relay module may be subcutaneously placed underneath the subject's skin. The relay module may be placed on the subject's skin. The relay module is placed on a wearable item.
The relay module may further include a position sensor configured to read positional information of the relay module. The position sensor comprises one of: a touch sensor, a gyroscope, or an accelerometer. The control module may be further configured to: receive the positional information from multiple relay modules; and choose a particular relay module to transmit the second RF signal to the implantable lead module, based on the positional information received, wherein the particular relay module chosen is better coupled to the implantable lead module than at least one other relay module.
In another aspect, a method of stimulating excitable tissue in a subject by using a relay module includes: transmitting a first RF signal from a first antenna on a control module; receiving, by the relay module, the first RF signal from the first antenna on the control module; generating, by the relay module, a second RF signal based on the first RF signal, the second RF signal containing power and encoding a stimulus waveform to be applied by the at least one electrodes of the implantable lead module to stimulate excitable tissue of the subject; transmitting, by the relay module, the second RF signal to an implantable lead module; receiving, by the implantable lead module the second RF signal; generating, by the implantable lead module the stimulation waveform; and applying, through at least one electrode on the implantable lead module, the stimulation waveform to the excitable tissue.
Implementations of this and other aspects may further include rectifying an initial portion of the first RF signal to provide energy to store a charge on the relay module; generating the second RF signal at an end of the initial portion; and amplifying the second RF signal by using the stored charge before transmitting the second RF signal.
The method may further include: generating the second RF signal based on a trigger caused by an amplitude shift keying in the first RF signal, the amplitude shift keying corresponding to the end of the initial portion of the first RF signal. The method may further include: generating the second RF signal based on a trigger caused by counting a number of cycles during the initial portion of the first RF signal.
The second RF pulse may include a portion to provide energy to power the implantable lead module. The method may further include: configuring polarity of at least one electrode of the implantable lead module based on a subsequent portion of the second RF signal that encodes polarity setting information of the at least one electrode.
The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.
The portable MFS device 100 includes an antenna 110. Antenna 110 may be configured to transmit a first radio frequency (RF) signal that propagates to relay module 130. The first RF signal may have a characteristic carrier frequency within a range from about 800 MHz to about 6 GHz.
As shown by
Relay module 130 may include a receive antenna 131 and a transmit antenna 132. Receive (Rx) antenna 131 is configured to receive the RF signal from antenna 110. The coupling between antenna 110 and Rx antenna 131 may be inductive, radiative, or any combinations thereof. The Rx antenna 131 may be coupled to transmit (Tx) antenna 132 by a dielectric insulating layer(s) and flexible circuits, as will be discussed in further detail below. The Tx antenna 132 transmits a second RF signal to an implantable lead module 140. The second RF signal may be derived from, or otherwise based on, the first RF signal and may or may not have the same characteristic carrier frequency of the first RF signal, as will be discussed in further detail below. A RF module 130 may use, for example, a conditioning circuit in combination with a power amplifier to shape and enhance the second RF signal before transmitting the second RF signal to implantable lead module 140, as will be discussed below in further detail.
An implantable lead module 140 has been implanted inside the body of a subject. The subject can be a live human or animal. The implantable lead module 140 is a passive device without an onboard power source, such as a battery. An implantable lead module 140 includes an antenna 141 configured to receive the second RF signal from antenna 132. The coupling between antenna 141 and Tx antenna 132 may be inductive, radiative, or any combinations thereof. The implantable lead module 140 includes one or more electrodes placed in close proximity to an excitable tissue, such as, for example, neural tissue. The second RF signal may contain energy to power the lead module 140, and may encode a stimulus waveform. The lead module 140 may generate the stimulus waveform from the second RF signal, and apply the stimulus waveform to the excitable tissue using the electrodes. Examples of the lead module 140 are described in, for example, U.S. patent application Ser. No. 13/584,618, filed on Aug. 13, 2012, the entire contents of which are incorporated herein by reference.
As illustrated by
The controller 202 can create the first RF signal to be transmitted from the antenna 110 to the relay module 130, which in turn may generate and transmit the second RF signal to the antenna 141 on the implantable lead module 140. As shown in
Memory 211 may be local memory on board of the portable MFS device 100. Memory 211 may include any type of non-volatile memories, such as, for example, EEPROM, flash memory, etc. Memory 211 may store stimulation parameter settings, such as for example, pulse amplitude, waveform shape, repetition frequency, pulse duration, etc. Based on the stored stimulation parameter settings, pulse generator 212 may generate stimulation waveforms. Modulator 213 may generate a carrier frequency, for example, within a range from about 600 MHz to about 6 GHz. The stimulation waveforms generated by pulse generator 212 may modulate the carrier frequency. The resulting modulated carrier frequency signal may be amplified by amplifier 214 to generate the first RF signal to be transmitted by antenna 110.
The controller 202 may receive input from the UI 203 and the feedback subsystem 204. UI 203 may include a Bluetooth circuit board, or a USB interface connector. UI 203 may include a programmer interface for a user, such as a manufacturer's representative, to adjust stimulation parameters, such as, for example, stimulation frequency, pulse width, power amplitude, duration of treatment, waveform shape, pre-programmed options and patient reminders. The programming interface can cause the selected settings to be stored on memory 211 of controller 202. The selected settings are used to create, for example, the appropriate stimulation waveforms for driving the electrodes on implantable lead module 140.
Feedback subsystem 204 also may provide input to the controller 202 in creating the first RF signal. The feedback may be based on measurements of reflected power on antenna 110. The reflected power may indicate the coupling between antenna 110 and surrounding medium, as will be discussed in further detail in association with
Antenna 110 may include a dipole antenna, a folded dipole antenna, a patch antenna, a microstrip antenna, or a phased array of antennas. Antenna 110 may be impedance matched to air to improve coupling efficiency with relay module 130. Antenna 110 can be located on the top of a flexible fixation housing that encloses the MFS circuitry connected with a low loss cable, or within the MFS enclosure, or remote from the MFS connected through a low loss cable.
In another example, shown in
Antenna 141 is configured to receive the second RF signal from antenna 132 on relay module 130. The Antenna 141 may be embedded as a dipole, a patch, a microstrip, folded dipole, other antenna configuration. The second RF signal may have a carrier frequency in the GHz range and contain electrical energy for powering the wireless implantable lead module 140 and for providing stimulation pulses to electrodes of implantable lead module. Once received by the antenna 141, the second RF signal is routed to power management circuitry 310 as the input signal.
Power management circuitry 310 is configured to rectify the input signal and convert it to a DC power source. For example, the power management circuitry 310 may include a diode rectification bridge and a capacitor. The rectification may utilize one or more full wave diode bridge rectifiers within the power management circuitry 310.
The DC power source provides power to the stimulation circuitry 311 and lead logic circuitry 313. Stimulation circuitry 311 may extract the stimulation waveforms from the received input signal. The stimulation waveforms may be shaped by pulse shaping RC timer circuitry 312 and then applied to the electrodes 322. Passive charge balancing circuitry 318 may balance charges applied at the electrodes. Lead logic circuitry 313 may detect a portion of the input signal containing polarity setting information for each electrode of the electrode array 322. This information may be used to set the polarity of electrode interface 314 controlling the polarity assignment of each electrode on electrodes 322. A particular electrode on the electrode array 322 may be implanted near target excitable tissue. The excitable tissue can be, for example, a cardiac tissue, a neural tissue, etc.
As discussed above, relay module 130 may be placed either in proximity of the tissue medium within a few millimeters or subcutaneously under the skin of a subject, such as a human or an animal. If placed outside the subject's body, the Rx antenna 131 may be coupled to the air and may be impedance-matched to the air. If placed subcutaneously, the Rx antenna 131 may still be coupled to the air since the skin layer covering the antenna is sufficiently thin, having minimal effect on the coupling efficiency between the antenna 110 and Rx antenna 131 of the relay module 130. The separation of the two conductor layers 404 and the electromagnetic properties of the insulator layer 405 may determine the resonant frequency of Rx antenna 131. Rx antenna 131 may generally be a quarter wavelength antenna at this resonant frequency.
The Tx antenna 132 in
Generally, a patch antenna may include a conducting material layer that serves as a conducting plane; a dielectric insulating plane the size of the conducting plane placed over the conducting layer; and another conducting layer, smaller than the ground plane, shaped in a desired pattern. If two patch antennas are separated by another insulating plane, as illustrated by
In
The flexible circuit may be placed relative to the Rx antenna 131 and the Tx antenna 132. For example,
The relay module 130 may operate in two modes, a relay mode and a repeater mode. In relay mode, the relay module 130 may not alter the stimulation portion of the received first RF signal when transmitting the second RF signal to the implantable lead module 140. In the repeater mode, however, the relay module 130 may enhance the stimulation portion of the received first RF signal when transmitting the second RF signal to the implantable lead module 140.
The first RF signal transmitted from the portable MFS device 100 contains two separate portions of encoded carrier waveforms. The first RF signal is received by Rx antenna 131 on relay module 130. A charging portion of the received first RF signal may contain a long (e.g., about 1 ms or above) burst of pulses at a carrier frequency. This charging portion may be the initial portion of a particular signal pattern to be repeated in the first RF signal. This charging portion is used to charge a power storage reservoir circuit including a capacitor 605 within the relay module 130. For example, the flexible circuit may contain a rectifier 601 to generate a DC power supply by rectifying and smoothing the initial portion of the received first RF signal. The DC power supply may store charges in, for example, capacitor 605. The stored charge may then be used to power subsequent operations of relay module 130. These subsequent operations may include, for example, subsequent transmission of the second RF signal that powers the electrodes on implantable lead module 140. Specifically, implantable lead module 140 is a passive device without a power supply. In contrast, some implementations of the relay module 130, however, may include a power source, such as a rechargeable battery. Once the second RF signal is received at the passive implantable lead module 140, it may be demodulated to provide the stimulation waveforms to be applied at the electrodes 322. As discussed above in association with
A stimulation portion of the received first RF signal encodes stimulus waveforms. This stimulation portion may be the later portion of the signal pattern being repeated in the first RF signal. The stimulation portion of the first RF signal will be conditioned by stimulus conditioning circuitry 602 before transmission to implantable lead module 140. The stimulus waveforms may contain short (e.g., about 0.5 ms or shorter) bursts of pulses. A low-noise amplifier 603 detects the stimulation portion of the first RF signal from Rx antenna 131 and feeds the stimulation portion to a high power amplifier 604. In one implementation, the first RF signal contains amplitude shift keying to indicate the end of the initial portion (for charging, e.g., capacitor 605) and the start of the stimulation portion. The amplitude shift keying may cause the stimulus conditioning circuitry 602 to generate a trigger to allow DC power to be received from the stored charge in capacitor 605. In another implementation, the stimulus conditioning circuit may include a counter that is set to expire upon a pre-determined number of pulse wave cycles. When the counter counts the number of pulse cycles in the received first RF signal has reached the pre-determined threshold, the counter will expire and generate a trigger. Upon the trigger, stored charge in capacitor 605 may be harvested to power, for example, stimulus conditioning circuit 602, low-noise amplifier 603 and power amplifier 604. In either example implementation, the output from the power amplifier 604 drives the Tx antenna 132 to transmit the amplified stimulus waveform at the original carrier frequency to the implantable lead module 140. The stored charge can be recharged by the next repetition of the initial portion in the first RF signal received from portable MFS device 100.
The first RF signal received from portable MFS device 100 by Rx antenna 131 contains two separate portions of encoded carrier waveforms. As discussed above, an initial portion of the first RF signal may contain a long (e.g., about 1 ms or above) burst of pulses at a carrier frequency. This initial portion is used to charge a power storage reservoir circuit including a capacitor 605 within the relay module 130. For example, the flexible circuit may contain a rectifier 601 to generate a DC power supply by rectifying and smoothing the initial portion of the first RF signal. The DC power supply may store charges in, for example, capacitor 605. The stored charge may then be used to power subsequent power subsequent operations of relay module 130. These subsequent operations may include, for example, subsequent transmission of the second RF signal that powers the electrodes on implantable lead module 140. As discussed above, implantable lead module 140 is a passive device without a power supply. In contrast, some implementations of the relay module 130, however, may include a power source, such as a rechargeable battery. Once the second RF signal is received at the passive implantable lead module 140, it may be demodulated to provide the stimulation waveforms to be applied at the electrodes 322. As discussed above in association with
A stimulation portion of the first RF signal encodes stimulus waveforms. This stimulation portion may be a later portion in a pattern being repeated in the first RF signal. The simulations portion of the first RF signal will be conditioned by stimulus conditioning circuitry 602 and further modulated by TX modulator 700 before transmission to implantable lead module 140. The stimulus waveforms contain short (e.g., about 0.5 ms or shorter) bursts of pulses. In one implementation, the first RF signal contains amplitude shift keying to indicate the end of the initial portion (for charging, e.g., capacitor 605) and the start of the stimulation portion. The amplitude shift keying may cause the stimulus conditioning circuitry 602 to generate a trigger to allow DC power to be received from the stored charge in capacitor 605. In another implementation, the stimulus conditioning circuit may include a counter that is set to expire upon a pre-determined number of pulse wave cycles. When the counted number of pulse cycles in the received first RF signal has reached the pre-determined threshold, the counter will expire and generate a trigger. Upon the trigger, stored charge in capacitor 605 may be harvested to power, for example, Tx modulator 700 and power amplifier 604. In either example implementation, the stimulus waveform is mixed with a carrier frequency of Tx modulator, the result is fed to power amplifier 604, and the output from the power amplifier 604 drives the Tx antenna 132 to transmit the amplified stimulus waveform modulated at the carrier frequency of Tx modulator 132 to the implantable lead module 140. As discussed above, the stored charge can be recharged by the next instance of the initial portion of the first RF signal received from portable MFS device 100.
In this mode, the carrier frequency of the first RF signal transmitted by the portable MFS device 100 can be decoupled from the carrier frequency of the stimulus waveform transmitted by the relay module 130. As long as the two carrier frequencies are sufficiently apart and the pass band of antenna 141 on implantable lead module 140 is sufficiently selective, the electrodes on the implantable lead module may only be driven by the stimulus waveform transmitted from relay module 130.
Multiple implantable lead modules 140 may be implanted inside a subject's body. Multiple relay modules 130 may be configured to relay energy from a portable MFS device 100 to the implantable lead modules 140.
Initially, a user may input stimulation parameters into the portable MFS device 100 (902). The stimulation parameters may include, for example, frequency, amplitude, pulse width, treatment duration, etc. These parameters may be entered into portable MFS device 100 through a programmer module, e.g., UI 203 (904). Afterwards, the portable MFS device 100 may send power to each relay module 130 (906). As discussed below in
Subsequently, the portable MFS device 100 may read the positional information generated by the position sensors at the respective relay module 130 (908). Based on the positional information collected, portable MFS device 100 may determine the relay module 130 best positioned to relay energy to power a particular implantable lead module 140. The relay module best positioned to relay energy may be the relay module with one of the following characteristics: the lowest amount of transmission loss, best coupling to tissue, closest proximity to the portable MFS device 100, or closest proximity to a particular implantable lead module 140. For example, a software algorithm may be implemented on the portable MFS device 100 to determine the position of a particular relay module 130 relative to a given implanted implantable lead module 130. The portable MFS device 100 may then determine which relay module should be selected to transmit energy most efficiently to the given implanted implantable lead module 130. In this example, the relay module that will transmit energy most efficiently to the given implantable lead module may be the relay module closest to the given implantable lead module. The portable MFS device 100 can digitally control a multiplexor to selectively transmit energy to a chosen relay module 130.
Thereafter, the portable MFS device 100 may generate the first RF signal by modulating a carrier signal with a particular stimulation waveform, for example, according to stimulation parameters stored in memory 211 (910). The portable MFS device 100 may then send the first RF signal to the optimal relay module as determined above (911). The selected optimal relay module may be the only relay module activated to receive the first RF signal. The activation may be achieved remotely by portable MFS device 100 before transmission of the first RF signal.
When the selected optimal relay module receives the first RF signal at its Rx antenna 131, the relay module may utilize a charging portion of the received first RF signal to charge a reservoir, such as, for example, capacitor 605, and then utilize the stored charge to power the relay circuitry (912). For example, the stored charge may be used to modulate a carrier wave with a stimulation waveform, amplifier the modulated carrier wave to provide the second RF signal, and then transmit the second RF signal to the given implantable lead module (914).
Subsequently, the given implantable lead module receives the second RF signal. As a passive device, the given implantable lead module is powered by the energy contained in the second RF signal and extracts the stimulation waveform from the received second RF signal (916). In capturing the energy contained in the second RF signal, the implantable lead module 140 may store a charge in a capacitor. The stored charge will be utilized to apply the extracted stimulation waveform to the electrodes 322 (918).
The right panel shows a profile view of the example configuration of relay module 130 with positional sensor 1000. Position sensor 1000 may be a component of the surface mount (SMT) components 507 mounted on flexible circuit 506. As discussed above, the Rx antenna 131 and the Tx antenna 132 may be implemented as patch-on-patch antennas. The Tx antenna 132 of each relay module 130 can be circularly polarized to substantially obviate directional dependence, thereby permitting a wider acceptance angle at the antenna 141 on implantable lead module 140.
In one implementation, a semiconductor gyroscope can be used as a position sensor to determine the orientation of Rx antenna 131 and Tx antenna 132. In other implementations, touch sensors can be used as a position sensor to detect, for example, if the Tx antenna 132 of the relay module 130 is coming in contact with an object. The touch sensor may also detect any force gradients to determine whether the side of Tx antenna 132 is touching something pliable, such as clothing, or something hard. In particular, when Tx antenna 132 is touching a lossy surface, like the thigh, it could be considered a worst case scenario. A lossy surface may have different impedance than the impedance of the antenna. When the Rx antenna 131 or the Tx antenna 132 is touching a side pocket material, or other clothing, antenna coupling could be closer to that of air coupling, which may be considered the best-case scenario.
In yet other implementations, an additional coupler can be used to detect the forward power and reflection outputted by a given Tx antenna 132. A lossy surface may be detected when the measured reflection measurement is high, such as, for example, over 25% of the transmission energy. The presence of a lossy surface on a particular relay module may provide feedback to portable MFS device 100 that the particular relay module should be avoided. As a result, an alert may be provided to UI 203 on portable MFS device 100 to notify a user of the situation. Unless the situation has been remedied, the portable MFS device 100 may refrain from using the given relay module to relay energy to an implantable lead module.
The design of the relay module 130 is intended to be convenient for patient use in daily activities such as exercise, working, and other leisure activities. A strap holding the relay module 130 over an implanted antenna 141 on implantable lead module 140 can become inconvenient in situations such as swimming, such as where the relay module 130 can shift, for example, during the sleeping time of the subject; or where the relay module 130 could press against the skin potentially uncomfortably. Additionally, bulky medical devices tend to be unaesthetic and are undesirable in many situations where skin is exposed.
The implementations discussed above address these issues by placing the pulse generator on the portable MFS device 100 wirelessly away from the body up to three feet. The implementations utilize a compact relay module 130 that may seamlessly integrate into a wearable item or be subcutaneously placed. The relay module 130 may relay energy received from portable MFS device 100 to power implantable lead module 140. Some implementations may further detect which relay module is in contact with lossy materials and guides the pulsed microwave energy from portable MFS device 100 to be directed to the relay module with the best coupling to a particular implantable lead module.
A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made. Accordingly, other implementations are within the scope of the following claims.
This application is a continuation of U.S. application Ser. No. 15/983,355, filed May 18, 2018, now allowed, which is a continuation of U.S. application Ser. No. 15/002,610, filed Jan. 21, 2016, now U.S. Pat. No. 9,974,965, issued May 22, 2018, which is a continuation of U.S. application Ser. No. 13/621,530, filed Sep. 17, 2012, now U.S. Pat. No. 9,242,103, issued Jan. 26, 2016, which claims the benefit of U.S. Provisional Application No. 61/535,295, filed Sep. 15, 2011, the entire contents of which are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
2990547 | McDougal | Jun 1961 | A |
3662758 | Glover | May 1972 | A |
3663758 | Erbert | May 1972 | A |
3727616 | Lenzkes | Apr 1973 | A |
4057069 | Dorffer et al. | Nov 1977 | A |
4102344 | Conway et al. | Jul 1978 | A |
4223679 | Schulman et al. | Sep 1980 | A |
4494950 | Fischell | Jan 1985 | A |
4524774 | Hildebrandt | Jun 1985 | A |
4525774 | Kino et al. | Jun 1985 | A |
4532930 | Crosby | Aug 1985 | A |
4561443 | Hogrefe et al. | Dec 1985 | A |
4592359 | Galbraith | Jun 1986 | A |
4612934 | Borkan | Sep 1986 | A |
4628933 | Michelson | Dec 1986 | A |
4665896 | LaForge | May 1987 | A |
4726378 | Kaplan | Feb 1988 | A |
4736747 | Drake | Apr 1988 | A |
4736752 | Munck | Apr 1988 | A |
4741339 | Harrison et al. | May 1988 | A |
4750499 | Hoffer | Jun 1988 | A |
4793353 | Borkan | Dec 1988 | A |
4837049 | Byers et al. | Jun 1989 | A |
4926879 | Sevrain | May 1990 | A |
4947844 | McDermott | Aug 1990 | A |
5058581 | Silvian | Oct 1991 | A |
5070535 | Hochmair et al. | Dec 1991 | A |
5193539 | Schulman et al. | Mar 1993 | A |
5262793 | Sperry | Nov 1993 | A |
5314458 | Najafi et al. | May 1994 | A |
5343766 | Lee | Sep 1994 | A |
5358514 | Schulman et al. | Oct 1994 | A |
5411535 | Fujii et al. | May 1995 | A |
5583510 | Ponnapalli et al. | Dec 1996 | A |
5591217 | Barreras | Jan 1997 | A |
5626630 | Markowitz et al. | May 1997 | A |
5735887 | Barreras, Sr. et al. | Apr 1998 | A |
5769877 | Barreras | Jun 1998 | A |
5861019 | Sun et al. | Jan 1999 | A |
5991664 | Seligman | Nov 1999 | A |
5995874 | Borza | Nov 1999 | A |
6141588 | Cox et al. | Oct 2000 | A |
6164284 | Shulman et al. | Dec 2000 | A |
6175752 | Say et al. | Jan 2001 | B1 |
6350335 | Hampel et al. | Feb 2002 | B1 |
6364889 | Kheiri et al. | Apr 2002 | B1 |
6415184 | Ishikawa et al. | Jul 2002 | B1 |
6445953 | Bulkes et al. | Sep 2002 | B1 |
6445955 | Michelson et al. | Sep 2002 | B1 |
6458157 | Suaning | Oct 2002 | B1 |
6463336 | Mawhinney | Oct 2002 | B1 |
D466487 | Wada et al. | Dec 2002 | S |
6516227 | Meadows et al. | Feb 2003 | B1 |
D474982 | Wilson | May 2003 | S |
6564807 | Schulman et al. | May 2003 | B1 |
6611715 | Boveja | Aug 2003 | B1 |
6615081 | Boveja | Sep 2003 | B1 |
6647296 | Fischell et al. | Nov 2003 | B2 |
6662052 | Sarwal et al. | Dec 2003 | B1 |
6684104 | Gordon et al. | Jan 2004 | B2 |
6690974 | Archer et al. | Feb 2004 | B2 |
6889086 | Mass et al. | May 2005 | B2 |
6895280 | Meadows et al. | May 2005 | B2 |
6972727 | West et al. | Dec 2005 | B1 |
7003350 | Denker et al. | Feb 2006 | B2 |
7027874 | Sawan et al. | Apr 2006 | B1 |
7110823 | Whitehurst et al. | Sep 2006 | B2 |
D529402 | Burton | Oct 2006 | S |
7177690 | Woods et al. | Feb 2007 | B2 |
7214189 | Zdeblick | May 2007 | B2 |
7277728 | Kauhanen | Oct 2007 | B1 |
7283875 | Larsson | Oct 2007 | B2 |
7317947 | Wahlstrand et al. | Jan 2008 | B2 |
7436752 | He | Oct 2008 | B2 |
7450992 | Cameron | Nov 2008 | B1 |
7471257 | Candal et al. | Dec 2008 | B2 |
7489248 | Gengel et al. | Feb 2009 | B2 |
7616991 | Mann et al. | Nov 2009 | B2 |
7620451 | Demarais | Nov 2009 | B2 |
7630771 | Cauller | Dec 2009 | B2 |
7664552 | Wahlstrand et al. | Feb 2010 | B2 |
D612543 | Marseille | Mar 2010 | S |
7729781 | Swoyer et al. | Jun 2010 | B2 |
7738964 | Von Arx et al. | Jun 2010 | B2 |
7741734 | Joannopoulos et al. | Jun 2010 | B2 |
7765013 | Blick et al. | Jul 2010 | B2 |
7853333 | Demarais | Dec 2010 | B2 |
7869885 | Begnaud et al. | Jan 2011 | B2 |
7894905 | Pless et al. | Feb 2011 | B2 |
7904170 | Harding | Mar 2011 | B2 |
7908014 | Schulman et al. | Mar 2011 | B2 |
7917226 | Nghiem et al. | Mar 2011 | B2 |
7939346 | Blick et al. | May 2011 | B2 |
D658302 | Nixon | Apr 2012 | S |
8170672 | Weiss et al. | May 2012 | B2 |
8242968 | Conrad et al. | Aug 2012 | B2 |
8320850 | Khlat | Nov 2012 | B1 |
8332040 | Winstrom | Dec 2012 | B1 |
8634928 | O'Drisco et al. | Jan 2014 | B1 |
D701504 | Christopher et al. | Mar 2014 | S |
D703204 | Riddiford et al. | Apr 2014 | S |
D714288 | Aumiller et al. | Sep 2014 | S |
8849412 | Perryman et al. | Sep 2014 | B2 |
8903502 | Perryman | Dec 2014 | B2 |
D721701 | Al-Nasser | Jan 2015 | S |
D725071 | Lee et al. | Mar 2015 | S |
D725072 | Kim et al. | Mar 2015 | S |
D725652 | Ishii | Mar 2015 | S |
D734330 | Huang et al. | Jul 2015 | S |
9199089 | Perryman et al. | Dec 2015 | B2 |
9220897 | Perryman et al. | Dec 2015 | B2 |
9242103 | Perryman | Jan 2016 | B2 |
9254393 | Perryman et al. | Feb 2016 | B2 |
9409030 | Perryman et al. | Aug 2016 | B2 |
9566449 | Perryman et al. | Feb 2017 | B2 |
9757571 | Perryman | Sep 2017 | B2 |
9789314 | Perryman | Oct 2017 | B2 |
9925384 | Perryman et al. | Mar 2018 | B2 |
9974965 | Perryman | May 2018 | B2 |
10238874 | Perryman | Mar 2019 | B2 |
10293169 | Perryman et al. | May 2019 | B2 |
10315039 | Perryman et al. | Jun 2019 | B2 |
10420947 | Larson et al. | Sep 2019 | B2 |
10471262 | Perryman et al. | Nov 2019 | B2 |
10953228 | Perryman et al. | Mar 2021 | B2 |
20010010662 | Saitou et al. | Aug 2001 | A1 |
20020058972 | Minogue et al. | May 2002 | A1 |
20020082668 | Ingman | Jun 2002 | A1 |
20020091420 | Minogue et al. | Jul 2002 | A1 |
20020095195 | Mass | Jul 2002 | A1 |
20020103513 | Minogue et al. | Aug 2002 | A1 |
20020123779 | Von Arx et al. | Sep 2002 | A1 |
20020128686 | Minogue et al. | Sep 2002 | A1 |
20020128693 | Minogue et al. | Sep 2002 | A1 |
20020133195 | Minogue et al. | Sep 2002 | A1 |
20030078633 | Firlik et al. | Apr 2003 | A1 |
20030114898 | Von Arx et al. | Jun 2003 | A1 |
20030114899 | Woods et al. | Jun 2003 | A1 |
20030139782 | Duncan et al. | Jul 2003 | A1 |
20030169207 | Beigel | Sep 2003 | A1 |
20030204224 | Torgerson et al. | Oct 2003 | A1 |
20040044385 | Fenn et al. | Mar 2004 | A1 |
20040059392 | Parramon et al. | Mar 2004 | A1 |
20040082979 | Tong et al. | Apr 2004 | A1 |
20040127942 | Yomtov et al. | Jul 2004 | A1 |
20040138723 | Malick et al. | Jul 2004 | A1 |
20040167587 | Thompson et al. | Aug 2004 | A1 |
20040176803 | Whelan et al. | Sep 2004 | A1 |
20040220621 | Zhou | Nov 2004 | A1 |
20040230263 | Samulski | Nov 2004 | A1 |
20040243208 | Jordan | Dec 2004 | A1 |
20050027207 | Westbrook et al. | Feb 2005 | A1 |
20050119716 | McClure et al. | Jun 2005 | A1 |
20050137668 | Khan | Jun 2005 | A1 |
20050245994 | Varrichio et al. | Nov 2005 | A1 |
20060001583 | Bisig | Jan 2006 | A1 |
20060003721 | Bisig | Jan 2006 | A1 |
20060047327 | Colvin et al. | Mar 2006 | A1 |
20060085039 | Hastings et al. | Apr 2006 | A1 |
20060085042 | Hastings et al. | Apr 2006 | A1 |
20060149331 | Man et al. | Jul 2006 | A1 |
20060161216 | Constance | Jul 2006 | A1 |
20060161225 | Sormann et al. | Jul 2006 | A1 |
20060178718 | Jordan | Aug 2006 | A1 |
20060206168 | Minogue et al. | Sep 2006 | A1 |
20060287686 | Cullen et al. | Dec 2006 | A1 |
20060289528 | Chiu et al. | Dec 2006 | A1 |
20070055322 | Forsberg et al. | Mar 2007 | A1 |
20070055324 | Thompson et al. | Mar 2007 | A1 |
20070066995 | Strother et al. | Mar 2007 | A1 |
20070100385 | Rawat | May 2007 | A1 |
20070100395 | Ibrahim | May 2007 | A1 |
20070100935 | Miyazaki et al. | May 2007 | A1 |
20070106337 | Errico et al. | May 2007 | A1 |
20070109208 | Turner | May 2007 | A1 |
20070112402 | Grill et al. | May 2007 | A1 |
20070123948 | Dal Molin | May 2007 | A1 |
20070156179 | S.E. | Jul 2007 | A1 |
20070208394 | King et al. | Sep 2007 | A1 |
20070213773 | Hill et al. | Sep 2007 | A1 |
20070213783 | Pless | Sep 2007 | A1 |
20070239224 | Bennett et al. | Oct 2007 | A1 |
20070254632 | Beadle et al. | Nov 2007 | A1 |
20070255223 | Phillips et al. | Nov 2007 | A1 |
20070255373 | Metzler et al. | Nov 2007 | A1 |
20070257636 | Phillips et al. | Nov 2007 | A1 |
20070265543 | VanSickle et al. | Nov 2007 | A1 |
20070265690 | Lichtenstein et al. | Nov 2007 | A1 |
20070288066 | Christman et al. | Dec 2007 | A1 |
20070293909 | Cowan et al. | Dec 2007 | A1 |
20080010358 | Jin | Jan 2008 | A1 |
20080046012 | Covalin et al. | Feb 2008 | A1 |
20080077184 | Denker et al. | Mar 2008 | A1 |
20080077188 | Denker et al. | Mar 2008 | A1 |
20080077189 | Ostroff | Mar 2008 | A1 |
20080103558 | Wenzel | May 2008 | A1 |
20080154217 | Carrez et al. | Jun 2008 | A1 |
20080161883 | Conor | Jul 2008 | A1 |
20080266123 | Ales et al. | Oct 2008 | A1 |
20080279896 | Heinen et al. | Nov 2008 | A1 |
20080281244 | Jacobs | Nov 2008 | A1 |
20090018599 | Hastings et al. | Jan 2009 | A1 |
20090099405 | Schneider et al. | Apr 2009 | A1 |
20090105784 | Massoud-Ansari | Apr 2009 | A1 |
20090105795 | Minogue et al. | Apr 2009 | A1 |
20090125091 | Schoenbach et al. | May 2009 | A1 |
20090132002 | Kieval | May 2009 | A1 |
20090132003 | Borgens et al. | May 2009 | A1 |
20090200985 | Zane et al. | Aug 2009 | A1 |
20090204170 | Hastings et al. | Aug 2009 | A1 |
20090234407 | Hastings et al. | Sep 2009 | A1 |
20090248112 | Mumbru et al. | Oct 2009 | A1 |
20090251101 | Phillips et al. | Oct 2009 | A1 |
20090270948 | Nghiem et al. | Oct 2009 | A1 |
20090270951 | Kallmyer | Oct 2009 | A1 |
20090292339 | Erickson | Nov 2009 | A1 |
20100010565 | Lichtenstein et al. | Jan 2010 | A1 |
20100053789 | Duric et al. | Mar 2010 | A1 |
20100114143 | Albrecht et al. | May 2010 | A1 |
20100114198 | Donofrio et al. | May 2010 | A1 |
20100125269 | Emmons et al. | May 2010 | A1 |
20100125312 | Stevenson et al. | May 2010 | A1 |
20100137938 | Kishawi et al. | Jun 2010 | A1 |
20100168818 | Barror et al. | Jul 2010 | A1 |
20100174340 | Simon | Jul 2010 | A1 |
20100179449 | Chow et al. | Jul 2010 | A1 |
20100198039 | Towe | Aug 2010 | A1 |
20100198307 | Toy et al. | Aug 2010 | A1 |
20100231382 | Tayrani et al. | Sep 2010 | A1 |
20100234919 | Minogue et al. | Sep 2010 | A1 |
20100234922 | Forsell | Sep 2010 | A1 |
20100241051 | Dacey, Jr. et al. | Sep 2010 | A1 |
20100268298 | Moffitt et al. | Oct 2010 | A1 |
20100269339 | Dye et al. | Oct 2010 | A1 |
20100298742 | Perlman et al. | Nov 2010 | A1 |
20100331934 | McDonald et al. | Dec 2010 | A1 |
20110029043 | Frysz et al. | Feb 2011 | A1 |
20110040350 | Griffith | Feb 2011 | A1 |
20110054563 | Janzig et al. | Mar 2011 | A1 |
20110074342 | MacLaughlin | Mar 2011 | A1 |
20110077698 | Tsampazis et al. | Mar 2011 | A1 |
20110098583 | Pandia et al. | Apr 2011 | A1 |
20110106220 | DeGiorgio et al. | May 2011 | A1 |
20110120822 | Kondou et al. | May 2011 | A1 |
20110121822 | Parsche | May 2011 | A1 |
20110125214 | Goetz et al. | May 2011 | A1 |
20110130804 | Lin et al. | Jun 2011 | A1 |
20110144468 | Boggs et al. | Jun 2011 | A1 |
20110152750 | Dacey, Jr. et al. | Jun 2011 | A1 |
20110166630 | Phillips et al. | Jul 2011 | A1 |
20110172733 | Lima et al. | Jul 2011 | A1 |
20110190849 | Faltys et al. | Aug 2011 | A1 |
20110208266 | Minogue et al. | Aug 2011 | A1 |
20110245892 | Kast et al. | Oct 2011 | A1 |
20110276108 | Crowe et al. | Nov 2011 | A1 |
20120004708 | Chen et al. | Jan 2012 | A1 |
20120004709 | Chen et al. | Jan 2012 | A1 |
20120116477 | Crowe et al. | May 2012 | A1 |
20120143282 | Fukui et al. | Jun 2012 | A1 |
20120158407 | Forsell | Jun 2012 | A1 |
20120194399 | Bily et al. | Aug 2012 | A1 |
20120215218 | Lipani | Aug 2012 | A1 |
20120239107 | Kallmyer | Sep 2012 | A1 |
20120283800 | Perryman et al. | Nov 2012 | A1 |
20120302821 | Burnett | Nov 2012 | A1 |
20120330384 | Perryman et al. | Dec 2012 | A1 |
20130016016 | Lin et al. | Jan 2013 | A1 |
20130066400 | Perryman et al. | Mar 2013 | A1 |
20130079849 | Perryman et al. | Mar 2013 | A1 |
20130131752 | Rawat | May 2013 | A1 |
20130018439 | Chow et al. | Jun 2013 | A1 |
20130165991 | Kim | Jun 2013 | A1 |
20130226262 | Stevenson et al. | Aug 2013 | A1 |
20130310901 | Perryman et al. | Nov 2013 | A1 |
20140031837 | Perryman et al. | Jan 2014 | A1 |
20140047713 | Singh et al. | Feb 2014 | A1 |
20140058480 | Perryman et al. | Feb 2014 | A1 |
20140058481 | Perryman et al. | Feb 2014 | A1 |
20140169142 | Heck et al. | Jun 2014 | A1 |
20140266935 | Tankiewicz | Sep 2014 | A1 |
20140336727 | Perryman et al. | Nov 2014 | A1 |
20150182753 | Harris et al. | Jul 2015 | A1 |
20150321017 | Perryman et al. | Nov 2015 | A1 |
20160101287 | Perryman | Apr 2016 | A1 |
20160136438 | Perryman et al. | May 2016 | A1 |
20160136439 | Andresen et al. | May 2016 | A1 |
20160339258 | Perryman et al. | Nov 2016 | A1 |
20160361535 | Perryman et al. | Dec 2016 | A1 |
20160367825 | Perryman et al. | Dec 2016 | A1 |
20170036033 | Perryman et al. | Feb 2017 | A9 |
20180008828 | Perryman | Jan 2018 | A1 |
20180169423 | Larson et al. | Jun 2018 | A1 |
20180236248 | Perryman | Aug 2018 | A1 |
20180264277 | Perryman | Sep 2018 | A1 |
20190229771 | Lee et al. | Jul 2019 | A1 |
20190247660 | Perryman | Aug 2019 | A1 |
20190381327 | Perryman et al. | Dec 2019 | A1 |
20200016415 | Perryman et al. | Jan 2020 | A1 |
20200016416 | Perryman et al. | Jan 2020 | A1 |
20200222703 | Perryman et al. | Jul 2020 | A1 |
20210275813 | Perryman et al. | Sep 2021 | A1 |
20220088398 | Perryman et al. | Mar 2022 | A1 |
20220126105 | Penyman et al. | Apr 2022 | A1 |
Number | Date | Country |
---|---|---|
1678370 | Oct 2005 | CN |
101185789 | May 2008 | CN |
101217320 | Jul 2008 | CN |
101352596 | Jan 2009 | CN |
101773701 | Jul 2010 | CN |
101842131 | Sep 2010 | CN |
201676401 | Dec 2010 | CN |
102120060 | Jul 2011 | CN |
2462981 | Jun 2001 | EP |
1588609 | Oct 2005 | EP |
2694154 | Jan 2018 | EP |
2341347 | Jun 2010 | ES |
H10 509901 | Sep 1998 | JP |
2002524124 | Aug 2002 | JP |
2005531371 | Oct 2005 | JP |
2008023353 | Feb 2008 | JP |
2008161667 | Jul 2008 | JP |
2008528222 | Jul 2008 | JP |
2009523402 | Jun 2009 | JP |
2010534114 | Nov 2010 | JP |
201155912 | Mar 2011 | JP |
2011510787 | Apr 2011 | JP |
2012508624 | Apr 2012 | JP |
WO 9620754 | Jul 1996 | WO |
WO 2000013585 | Mar 2000 | WO |
WO 2004002572 | Jan 2004 | WO |
WO 2004004826 | Jan 2004 | WO |
WO 2006113802 | Oct 2006 | WO |
WO2006128037 | Nov 2006 | WO |
WO 2007059386 | May 2007 | WO |
WO 2007081971 | Jul 2007 | WO |
WO 2009015005 | Jan 2009 | WO |
WO 2010005746 | Jan 2010 | WO |
WO 2010051189 | May 2010 | WO |
WO 2010053789 | May 2010 | WO |
WO 2010057046 | May 2010 | WO |
WO 2010104569 | Sep 2010 | WO |
WO 2011079309 | Jun 2011 | WO |
WO 2012103519 | Aug 2012 | WO |
WO 2012138782 | Oct 2012 | WO |
WO 2013019757 | Feb 2013 | WO |
WO 2013025632 | Feb 2013 | WO |
WO 2013040549 | Mar 2013 | WO |
Entry |
---|
US 5,197,469 A, 03/1993, Adams (withdrawn) |
Extended European Search Report in European Appln No. 20738285.4, dated Aug. 17, 2022, 5 pages. |
U.S. Appl. No. 14/445,159, filed Nov. 13, 2014, Perryman et al. |
U.S. Appl. No. 29/478,687, filed Jan. 7, 2003, Perryman et al. |
CA Office Action in Canadian Appln. No. 2831138, dated Oct. 30, 2020, 4 pages. |
CN OA in Chinese Appln. No. 201710675346.5, dated Jun. 1, 2020, 11 pages (with English translation). |
EP European Search Report in European Appln. No. 12831083.6, dated Aug. 17, 2015, 9 pages. |
EP European Search Report in European Appln. No. 17208566.4, dated Sep. 26, 2018, 10 pages. |
EP Extended European Search Report in European Appln. No. 18150779.9, dated May 9, 2018, 7 pages. |
EP Office Action in European Appln. No. 12740011.7, dated Sep. 18, 2018, 5 pages. |
European Search Report in European Appln. No. 12767575.9, dated Jan. 11, 2018, 6 pages. |
European Search Report in European Appln. No. 19186209, dated Nov. 25, 2019, 9 pages. |
Extended European Search report in Appln. No. 12740011.7, dated Sep. 9, 2015, 6 pages. |
Extended European Search report in Appln. No. 12767575.9, dated Nov. 7, 2014, 7 pages. |
Extended European Search Report in Appln. No. 1281083.6, dated Aug. 17, 2015, 9 pages. |
Extended European Search report in Appln. No. 12819482.6, dated Apr. 28, 2015, 7 pages. |
Extended European Search Report in Appln. No. 12824347.4, dated Apr. 22, 2015, 6 pages. |
Extended European Search Report in Appln. No. 15793285.6, dated Dec. 12, 2017, 7 pages. |
Iannetta [online], “Nov. 2014 New Products: Wearable coil facilities positioning during prostate MRI,” Urology Times, retrieved on Nov. 10, 2014, retrieved from<URL: http://urologytimes.modernmedicine.com/urology-times/news/november-2014-new-products-wearable-coil-facilitates-positioning-during-prostate-mri?page=full>, 7 pages. |
IL Office Action in Israeli Appln. No. 256280.0, dated Sep. 16, 2020, 9 pages (with English Translation). |
O'Driscoll et al., “A mm-Sized implantable power receiver with adaptive link compensation.” Poster, Presented at IEEE International Solid-State Circuits Conference, Session 17, 2009, 3 pages. |
PCT International Preliminary Report on Patentability and Written Opinion in International Appln. No. PCT/US2012/023029, dated Jan. 28, 2014, 10 pages. |
PCT International Preliminary Report on Patentability and Written Opinion in International Appln. No. PCT/US2012/032200 dated Oct. 8, 2013, 11 pages. |
PCT International Preliminary Report on Patentability and Written Opinion in International Appln. No. PCT/US2012/048903, dated Mar. 25, 2014, 8 pages. |
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2013/077846, dated Jun. 30, 2015, 6 pages. |
PCT International Preliminary Report on Patentability issued in International Appl. No. PCT/US2012/055746, dated Jan. 2, 2013, 10 pages. |
PCT International Preliminary Report on Patentability issued in International Appln. No. PCT/US2012/050633, dated Feb. 18, 2014, 7 pages. |
PCT International Search Report and PCT Written Opinion of the International Searching Authority in International Appln. No. PCT/US2012/055746, dated Jan. 3, 2013, 11 pages. |
PCT International Search Report and the Written Opinion in Appln. No. PCT/US2012/048903 dated Oct. 10, 2012, 9 pages. |
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2012/023029, dated May 16, 2012, 10 pages. |
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2012/032200, dated Jul. 27, 2012, 12 pages. |
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2012/050633 dated Oct. 23, 2012, 7 pages. |
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2013/077846 dated Apr. 21, 2014, 10 pages. |
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/013155, dated Apr. 1, 2020, 8 pages. |
pharad.com [online], “Assembly, Wearable Antenna, 350-450 MHz,” retrieved on Oct. 14, 2010, retrieved from URL< http://www.pharad.com/pdf/UHF-Wearable-Antenna-2D.pdf>, 1 page. |
Poon et al., “Optimal frequency for wireless power transmission into dispersive tissue,” IEEE Transactions on Antennas and Propagation, May 2010, 58(5):1739-1750. |
wirelessdesignmag.com [online], “Pharad at Forefront of LTE Antenna Innovation with Development of LTE Wearable Antenna,” retrieved on Aug. 12, 2012, retrieved from<URL:http://www.wirelessdesignmag.com/product-release/2013/08/pharad-forefront-lte-antenna-innovation-development-lte-wearable-antenna>, 3 pages. |
EP Extended European Search Report in European Appln. No. 20209052.8, dated Apr. 14, 2021, 7 pages. |
International Preliminary Report on Patentability in International Appln. No. PCT/US2020/013155, dated Jul. 22, 2021, 8 pages. |
Search Report in European Appln. No. 21164580.9, dated Oct. 22, 2021, 8 pages. |
Number | Date | Country | |
---|---|---|---|
20210187311 A1 | Jun 2021 | US |
Number | Date | Country | |
---|---|---|---|
61535295 | Sep 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15983355 | May 2018 | US |
Child | 17193191 | US | |
Parent | 15002610 | Jan 2016 | US |
Child | 15983355 | US | |
Parent | 13621530 | Sep 2012 | US |
Child | 15002610 | US |